John Overdeck’s TG Therapeutics TGTX Stock Holding History

John Overdeck’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.28M	Buy	+23,300	New	+$954K	﹤0.01%	3419

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

John Overdeck's TGTX Position: Q2 2026 in Review

John Overdeck increased its TG Therapeutics (TGTX) stake by 60% in Q2 2026, buying an estimated $37.9M and bringing the position to 2,468,971 shares worth $136M. The position accounts for 0.1% of the portfolio, ranked #228.

John Overdeck first reported a position in TGTX in Q4 2013 and has held it in 28 quarters since. 426 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

John Overdeck held 2,468,971 shares of TG Therapeutics worth $136M as of Q2 2026.
John Overdeck bought 926,659 TG Therapeutics shares in Q2 2026, an estimated $37.9M.
TG Therapeutics made up 0.1% of John Overdeck's portfolio in Q2 2026, its #228 holding.
John Overdeck first reported a position in TG Therapeutics in Q4 2013 and has held it in 28 quarters since.
426 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.